📣 New paper out in which we mapped what policies contribute to the regulatory landscape for #artificialintelligence in #health in the #EU 🔗 https://t.co/PWQRDOdWp3 👇Check out the thread below by co-author @robinvankessel for a synopsis

Another awesome thread from one of our super community of authors! See below @robinvankessel's synopsis of this paper describing the policies that contribute to the regulatory landscape for #ArtificialIntelligence in health within the EU. https://t.co/eexXvonzyU Full thread

A major thanks to #JelenaSchmidt, @Nienke_Schutte, @stefanbuttigieg , @davidnovillo , @esutherland272, Michael Anderson, @hippoai, Michael Peolsson, Brigid Unim, @MilPavlova , @arieldora , and @MOSSIALOS for their invaluable contributions and collaboration

#Industry professionals need clarity on the regulatory landscape for health innovations. Our article describes this landscape, ranging from the way data can be processed to the relevant legislation that regulates the market access pathways for AI-enabled #healthtechnologies.

#Researchers require a well-defined framework guided by AI legislation that encompasses the development of the AI technology and its outputs. Our article offers a comprehensive framework, providing legal guidance for all aspects pertaining to AI.

#Policymakers need a thorough understanding of the highly interconnected nature of #AI. Our article highlights how various legislative dimensions come together to form a regulatory framework that applies to AI in #healthcare and #populationhealth.

#Clinicians, #patients, and #citizens need clarity on how their rights are captured and safeguarded in legislation and how they can exercise these rights. Our article describes how health and #humanrights are an integral part of an AI regulatory framework.

The insights of our paper are particularly timely around the release of the #AIAct, seeing how different stakeholder groups are grappling with navigating the regulatory landscape for AI in health:

We explored what policies contributed to the regulatory landscape for #artificialintelligence in #health. The regulatory landscape consists of five domains: (1) AI regulation; (2) Data processing; (3) Technology appraisal; (4) Supporting innovation; and (5) Health & human rights.

I am delighted to share our latest paper published #OpenAccess in @npjDigitalMed: "Mapping the regulatory landscape for #ArtificialIntelligence in #health within the #EuropeanUnion." Link to the full-text:

New! Our paper in @PLOSDigiHealth on remote consultations in #primarycare offers a set of guiding principles that can facilitate the assessment of #virtualprimarycare. https://t.co/OsyonHQQOj @robinvankessel @marinedelgrange Avi Cherla @hssood @MOSSIALOS

A new study on #DigitalHealth reimbursement is out, led by @robinvankessel and @MOSSIALOS, and supported by @WHO_Europe. We explored reimbursement practices in 9 countries (🇧🇪🇫🇷🇩🇪🇮🇱🇮🇹🇳🇱🇵🇱🇸🇪🇬🇧). Let's unpack some key insights in a short thread.👇 https://t.co/Pz4dYo2QNj

Our paper on the need to conceptualise clearly the intersection between #digitalhealth and principles of #valuebased #pricing #reimbursement! @robinvankessel @ekyriopoulos Giovanni Monti @davidnovillo Ran Milman @gretanasi @arieldora @gawharton1 @MOSSIALOS

A big thank you to all collaborators that helped create this article: @divyasrivast, @ekyriopoulos, Giovanni Monti, @davidnovillo, Ran Milman, Wojciech Wilhelm Zhang-Czabanowski, @gretanasi, @arieldora, @gawharton1, and @MOSSIALOS

An increased emphasis on developing a clear conceptualisation of #digitalhealth, as well as #valuebased #pricing and #reimbursement mechanisms, are needed for the sustainable #uptake of #digitalhealth.

#European countries show #valuebased pricing frameworks that range from non-existent to embryonic. Financing #digitalhealth solutions outside traditional reimbursement schemes was possible in all studied countries except Poland.

We found that #pricing of #digitalhealth solutions are mostly determined through discussions between national or regional committees and the #digitalhealth manufacturers in absence of #valuebased assessment frameworks.

While various emergency reimbursement decisions were made during the #COVID19 pandemic to allow the use of healthcare delivery through #videoconferencing and asynchronous care, such tools represent only a small set of #digitalhealth approaches.

Having robust reimbursement mechanisms in place is a vital factor in ensuring the #sustainable #uptake of new #health technologies.

Proud to share our new publication in @jmirpub @JMIR_mHealth where we mapped #digitalhealth #reimbursement practices in nine countries in @WHO_Europe: Belgium, France, Germany, Israel, Italy, Netherlands, Poland, Sweden, and the UK. Read it #OpenAccess: https://t.co/b2YuqYe35D